Marshall Edwards, Inc., Presentation at the 25th Annual JPMorgan Healthcare Conference to be Webcast.
January 08 2007 - 8:59AM
PR Newswire (US)
WASHINGTON, Jan 8 /PRNewswire-FirstCall/ -- The Marshall Edwards,
Inc. (NASDAQ:MSHL) presentation to be made at the 25th Annual
JPMorgan Healthcare Conference in San Francisco on Wednesday
January 10, 2007 is at the revised time of 1:30 pm and will be
Webcast. The Webcast can be accessed with the following link:
https://events.jpmorgan.com/ and then click on the Webcast link.
About Marshall Edwards, Inc. Marshall Edwards, Inc., has licensed
rights from Novogen Limited (NASDAQ:NVGN) to bring three oncology
drugs -- phenoxodiol, NV-196 and NV-143 -- to market globally.
Marshall Edwards, Inc. is majority owned by Novogen, an Australian
biotechnology company that is specializing in the development of
therapeutics based on regulation of the sphingomyelin pathway.
Novogen, based in Sydney, Australia, is developing a range of
therapeutics across the fields of oncology, cardiovascular disease
and inflammatory diseases. More information on phenoxodiol and on
the Novogen group of companies can be found at
http://www.marshalledwardsinc.com/ and http://www.novogen.com/.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements. DATASOURCE:
Marshall Edwards Inc. CONTACT: David Sheon, +1-202-518-6321 or ,
for Marshall Edwards Inc. Web site:
http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024